Radiation-Induced Vaccination to Breast Cancer
Abstract
This study combines the TGFbeta neutralizing antibody, Fresolimumab, with Radiation Therapy (RT) to treat metastatic breast cancer. Fresolimumab is administered intravenously (i.v.) at either 1mg/kg or 10mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and RT administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2). The primary objectives are 1) to assess safety, feasibility and tumor regression 2) to monitor immune responses in these patients and 3) to correlate immune responses with abscopal effects assessed by imaging. Blood samples are obtained from patients before, during and after treatment and immune monitoring is performed at UCLA (Figure 1). In addition, Fresolimumab is examined at UCLA for its potential effects on breast cancer stem cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA569017
Entities
People
- William H. Mcbride
Organizations
- University of California, Los Angeles